GeoVax Labs Files 8-K on Financials
Ticker: GOVX · Form: 8-K · Filed: May 15, 2024 · CIK: 832489
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: GOVX
TL;DR
GeoVax Labs dropped an 8-K on May 14th covering financials - check it out.
AI Summary
GeoVax Labs, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition as of May 14, 2024. The filing includes financial statements and exhibits, but does not detail specific financial figures or operational outcomes within the provided text.
Why It Matters
This 8-K filing provides an update on GeoVax Labs' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, without immediate indication of significant negative events.
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
- May 15, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but does not specify the actual financial figures or operational outcomes within this excerpt.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is May 14, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed on May 15, 2024.
What is the Commission File Number for GeoVax Labs, Inc.?
The Commission File Number for GeoVax Labs, Inc. is 001-39563.
In which state was GeoVax Labs, Inc. incorporated?
GeoVax Labs, Inc. was incorporated in Delaware.
Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-05-15 16:03:35
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share GOVX The Nasdaq Capital Ma
Filing Documents
- govx20240514_8k.htm (8-K) — 27KB
- ex_674316.htm (EX-99.1) — 77KB
- logo01.jpg (GRAPHIC) — 14KB
- 0001437749-24-017040.txt ( ) — 280KB
- govx-20240514.xsd (EX-101.SCH) — 4KB
- govx-20240514_def.xml (EX-101.DEF) — 13KB
- govx-20240514_lab.xml (EX-101.LAB) — 17KB
- govx-20240514_pre.xml (EX-101.PRE) — 13KB
- govx20240514_8k_htm.xml (XML) — 5KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the "Filings") contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by the Company's management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to the Company or the Company's management identify forward looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company's industry, operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Company does not undertake to update its forward-looking statements.
02
Item 2.02 Results of Operations and Financial Condition. On May 14, 2024, GeoVax Labs, Inc. (the "Company") issued a press release reporting its results of operations for the quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 15, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer 3